^
No biomarker
Esophageal Adenocarcinoma
nivolumab
Sensitive
:
A1
FDA - 3wk
No biomarker
Esophageal Adenocarcinoma
ramucirumab
Sensitive
:
A2
HER-2 positive
Esophageal Adenocarcinoma
trastuzumab
Sensitive
:
A2
HER-2 overexpression
Esophageal Adenocarcinoma
trastuzumab
Sensitive
:
A2
PD-L1 expression
Esophageal Adenocarcinoma
pembrolizumab
Sensitive
:
A2
No biomarker
Esophageal Adenocarcinoma
FP
Sensitive
:
A2
No biomarker
Esophageal Adenocarcinoma
FLOT
Sensitive
:
A2
HER-2 Negative + PD-L1 expression
Esophageal Adenocarcinoma
nivolumab
Sensitive
:
A2
No biomarker
Esophageal Adenocarcinoma
FOLFOX
Sensitive
:
A2
HER-2 overexpression
Esophageal Adenocarcinoma
fam-trastuzumab deruxtecan-nxki
Sensitive
:
A2
PD-L1 expression
Esophageal Adenocarcinoma
nivolumab
Sensitive
:
B
HER-2 positive
Esophageal Adenocarcinoma
trastuzumab + pertuzumab
Sensitive
:
C1
CLDN18.2 expression
Esophageal Adenocarcinoma
IMAB362
Sensitive
:
C2
HER-2 amplification
Esophageal Adenocarcinoma
trastuzumab + avelumab
Sensitive
:
C2
HER-2 positive
Esophageal Adenocarcinoma
paclitaxel
Resistant
:
C3
HER-2 positive
Esophageal Adenocarcinoma
carboplatin
Resistant
:
C3
DKK1 overexpression
Esophageal Adenocarcinoma
pembrolizumab + DKN-01
Sensitive
:
C3
DKK1 overexpression
Esophageal Adenocarcinoma
DKN-01
Sensitive
:
C3
GRB7 positive
Esophageal Adenocarcinoma
trastuzumab + carboplatin + paclitaxel + pertuzumab
Sensitive
:
C3
HER-2 overexpression
Esophageal Adenocarcinoma
trastuzumab + pertuzumab
Sensitive
:
C3
ERCC1 negative
Esophageal Adenocarcinoma
SOX
Sensitive
:
C3
MSI-H/dMMR + MLH1 deletion + PMS2 deletion
Esophageal Adenocarcinoma
pembrolizumab
Sensitive
:
C4
VERI is free for non-commercial use, no login needed.
Content on this site is for research purposes only and is not intended  to be a substitute for medical advice.
For commercial access, including additional premium features, please contact us.
By using VERI, you are agreeing to our